ARTICLE | Clinical News
Anti-hepatitis B hyperimmune globulin regulatory update
October 1, 2001 7:00 AM UTC
CNJ submitted a BLA to the FDA for its anti-hepatitis B hyperimmmune globulin therapy for post-exposure prevention of hepatitis B virus infection. ...